Dynamic changes in single nucleotide mutations were well correlated with the patient's tumor burden, ctDNA mutation profiles accurately assessed the patient's tumor burden with high consistency as compared with imaging results, and ctDNA mutation profiles could discover tumor occurrence early in advance of imaging for an average of 4.6 months and showed superior performance as compared with serum biomarkers AFP and DCP (187). Here, AFP is linked to neoplasm.